BioWorld

Smsbiotech’s small mobile stem cell therapy cleared to enter clinic for COPD

Smsbiotech Inc. has gained clearance in Australia to begin a phase I trial of its small mobile stem (SMS) cell therapy for chronic obstructive pulmonary disease (COPD).

COPD Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Amgen, Synairgen, AstraZeneca, Sanofi, Organicell Regen…

The Chronic Obstructive Pulmonary Disease Pipeline report embraces in-depth commercial and clinical assessment of the ...

Hemostemix Granted Trademark "KNOW YOUR HEALTH" in Japan, International Registration No. 1744775 Covers Stem Cell Preparations and Research in Classes 1, 5, 42

Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to no-option individuals suffering from angina, ...

3D Printed Lungs Made With Living Cells May Be Treatment ‘Game Changer’

The development could help scientists develop patient-specific treatments and one day offer a lab-grown lung transplant ...

Molecular switch discovery may unlock regenerative therapies for lung disease

Mayo Clinic researchers have identified a molecular "switch" in lung cells that helps them decide when to repair tissue and ...